These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 2480846)
1. Stimulation of non-specific resistance to tumors in the mouse using a poly(maleic-acid-styrene)-conjugated neocarzinostatin. Suzuki F; Pollard RB; Maeda H Cancer Immunol Immunother; 1989; 30(2):97-104. PubMed ID: 2480846 [TBL] [Abstract][Full Text] [Related]
2. Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer-conjugated derivative of neocarzinostatin. Suzuki F; Pollard RB; Uchimura S; Munakata T; Maeda H Cancer Res; 1990 Jul; 50(13):3897-904. PubMed ID: 2141295 [TBL] [Abstract][Full Text] [Related]
3. Interferon induction by SMANCS: a polymer-conjugated derivative of neocarzinostatin. Suzuki F; Munakata T; Maeda H Anticancer Res; 1988; 8(1):97-103. PubMed ID: 2451896 [TBL] [Abstract][Full Text] [Related]
4. [Tumor growth inhibitory effects of SMANCS, a poly (styrene-maleic acid) conjugated derivative of neocarzinostatin, on various tissue culture cells]. Suzuki F; Okuno Y; Maeda Y; Maeda H Gan To Kagaku Ryoho; 1987 Dec; 14(12):3305-12. PubMed ID: 2961306 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of orally administered SMANCS, a polymer-conjugated protein drug, in mice bearing various murine tumors. Schmitt DA; Kisanuki K; Kimura S; Oka K; Pollard RB; Maeda H; Suzuki F Anticancer Res; 1992; 12(6B):2219-24. PubMed ID: 1295469 [TBL] [Abstract][Full Text] [Related]
6. Immunomodulating activities of orally administered SMANCS, a polymer-conjugated derivative of the proteinaceous antibiotic neocarzinostatin, in an oily formulation. Suzuki F; Matsumoto K; Schmitt DA; Pollard RB; Maeda H Int J Immunopharmacol; 1993 Feb; 15(2):175-83. PubMed ID: 7682198 [TBL] [Abstract][Full Text] [Related]
7. Differential neutralizing effect of tiopronin on the toxicity of neocarzinostatin and SMANCS: a new rescue cancer chemotherapy. Oda T; Yamamoto H; Miki T; Maeda H Jpn J Cancer Res; 1989 Apr; 80(4):394-9. PubMed ID: 2526108 [TBL] [Abstract][Full Text] [Related]
8. Styrene maleic acid neocarzinostatin treatment for hepatocellular carcinoma. Abe S; Otsuki M Curr Med Chem Anticancer Agents; 2002 Nov; 2(6):715-26. PubMed ID: 12678722 [TBL] [Abstract][Full Text] [Related]
9. Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane. Oda T; Morinaga T; Maeda H Proc Soc Exp Biol Med; 1986 Jan; 181(1):9-17. PubMed ID: 2935880 [TBL] [Abstract][Full Text] [Related]
10. In vitro mode of action, pharmacokinetics, and organ specificity of poly (maleic acid-styrene)-conjugated neocarzinostatin, SMANCS. Takeshita J; Maeda H; Kanamaru R Gan; 1982 Apr; 73(2):278-84. PubMed ID: 6214446 [TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of SMANCS on rat mammary tumor induced by 7,12-dimethylbenz[a]anthracene. Kimoto A; Konno T; Kawaguchi T; Miyauchi Y; Maeda H Cancer Res; 1992 Feb; 52(4):1013-7. PubMed ID: 1531320 [TBL] [Abstract][Full Text] [Related]
12. Combined effect of radiation and YM-881 (SMANCS) on murine tumors and bone marrow. Ono K; Wandl E; Sasai K; Tsutsui K; Shibamoto Y; Takahashi M; Abe M Acta Oncol; 1990; 29(4):455-9. PubMed ID: 2143908 [TBL] [Abstract][Full Text] [Related]
13. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH. Oda T; Sato F; Maeda H J Natl Cancer Inst; 1987 Dec; 79(6):1205-11. PubMed ID: 2961908 [TBL] [Abstract][Full Text] [Related]
14. Antitumor resistance induced by zinostatin stimalamer (ZSS), a polymer-conjugated neocarzinostatin (NCS) derivative. I. Meth A tumor eradication and tumor-neutralizing activity in mice pretreated with ZSS or NCS. Masuda E; Maeda H Cancer Immunol Immunother; 1995 May; 40(5):329-38. PubMed ID: 7600566 [TBL] [Abstract][Full Text] [Related]
15. Reduction of hepatic metastases in rabbits by administration of an oily anticancer agent into the portal vein. Yamasaki K; Konno T; Miyauchi Y; Maeda H Cancer Res; 1987 Feb; 47(3):852-5. PubMed ID: 3026619 [TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of smancs in comparison with other anticancer agents against various cells in culture. Oda T; Sato F; Yamamoto H; Akagi M; Maeda H Anticancer Res; 1989; 9(2):261-5. PubMed ID: 2526613 [TBL] [Abstract][Full Text] [Related]
17. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Maeda H Adv Drug Deliv Rev; 2001 Mar; 46(1-3):169-85. PubMed ID: 11259839 [TBL] [Abstract][Full Text] [Related]
18. [CT image of the liver cancer after administration of SMANCS/lipiodol]. Maki S; Konno T; Iwai K; Tashiro S; Otsuka N; Yamasaki K; Mizutani J; Miyauchi Y; Maeda H; Yokoyama I Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1603-10. PubMed ID: 3015036 [TBL] [Abstract][Full Text] [Related]
19. Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, smancs, in an oily formulation. Oka K; Miyamoto Y; Matsumura Y; Tanaka S; Oda T; Suzuki F; Maeda H Pharm Res; 1990 Aug; 7(8):852-5. PubMed ID: 2146602 [TBL] [Abstract][Full Text] [Related]
20. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Matsumura Y; Maeda H Cancer Res; 1986 Dec; 46(12 Pt 1):6387-92. PubMed ID: 2946403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]